98 related articles for article (PubMed ID: 11326676)
1. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
Lüfter D; Richter A; Günther S; Flath B; Akrivakis C; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5099-105. PubMed ID: 11326676
[TBL] [Abstract][Full Text] [Related]
2. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
3. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer.
Lüftner D; Richter A; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):1017-26. PubMed ID: 12820341
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
5. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
[TBL] [Abstract][Full Text] [Related]
6. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
Hou MF; Lin SB; Yuan SS; Tsai LY; Tsai SM; Hsieh JS; Huang TJ
Ann Clin Lab Sci; 2003; 33(1):55-61. PubMed ID: 12661898
[TBL] [Abstract][Full Text] [Related]
9. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
[TBL] [Abstract][Full Text] [Related]
10. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
11. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
12. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
16. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease.
Topkan E; Karaoglu A
J Exp Clin Cancer Res; 2007 Dec; 26(4):553-9. PubMed ID: 18365552
[TBL] [Abstract][Full Text] [Related]
17. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract][Full Text] [Related]
18. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
19. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Polico C; Nascimben O; Maccari F; Fazzin G
Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
[TBL] [Abstract][Full Text] [Related]
20. Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
Cen P; Duvic M; Cohen PR; Kurzrock R
J Am Acad Dermatol; 2008 Mar; 58(3):382-6. PubMed ID: 18280334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
